Contact Us

Suggested region and language based on your location

    Your current region and language

    Scientist Works with Petri Dishes with Various Bacteria, Tissue and Blood Samples
    • Case Study
      Health & Safety

    Demonstrating Commitment to the Responsible Manufacture of Antibiotics

    GSK: First pharmaceutical company with BSI Kitemark™ for Minimized Risk of AMR at all antibiotic sites.

    Testimonial

    “Achieving BSI Kitemark certification for all of our antibiotic manufacturing sites is a clear demonstration of GSK’s commitment to addressing AMR.” 

    Regis Simard President, Global Supply Chain, GSK
    female scientist in a busy research
    About GSK

    A global biopharma company committed to getting ahead of AMR

    GSK is a company focused on uniting science, technology, and talent to get ahead of disease and positively impact the health of billions of people.

    The company has set ambitious goals for both climate and nature, including a commitment to stay below Predicted No-Effect Concentration levels as defined by the AMR Industry Alliance and API Wastewater discharge limits. GSK first met this target in 2025 and continues to work to maintain this performance.

    The Challenge

    Ensuring API emissions from manufacturing are kept below levels that negatively impact human health or the environment

    The World Health Organization names antimicrobial resistance (AMR) a top global public health threat. It causes over 1 million deaths a year and, without action, almost 40 million by 2050.

    If not properly controlled, waste from antibiotic manufacturing can enter the environment, for example through wastewater, and contribute to AMR, reducing how well antibiotics treat infections. GSK already had a formalized programme to minimize AMR risk across its internal and manufacturing supply chains. Kitemark certification takes this further, independently verifying GSK’s responsible manufacturing practices and commitment to protecting public health and the environment.

    The Solution

    Demonstrating transparency, accountability and a commitment to addressing the global challenge of AMR

    GSK set out to enhance its existing AMR programme and documentation procedures to gain the BSI Kitemark for Minimized Risk of Antimicrobial Resistance at every antibiotic site.

    In 2024, GSK’s Worthing site became the first in the UK to achieve the Kitemark, following BSI audits of seven antibiotic products, wastewater treatment operations and storage areas. Certification involves an independent initial assessment followed by annual surveillance. With the certification of its final site in November 2026, GSK became the first pharmaceutical company to certify all of its antibiotic manufacturing sites worldwide, meeting its target for every site to be certified by the end of 2026.

    The Benefits

    How BSI Kitemark certification across all its antibiotic manufacturing sites is helping GSK to address AMR and achieve its environmental goals:

    People discussing in the office
    • down arrow

      Assurance that the antibiotics manufacturing process meets the highest international standard.

    • home icon

      Demonstrates its commitment to addressing AMR and minimizing antimicrobial waste in the environment.

    • plus icon

      Ensures waste streams containing APIs and drug products are suitably controlled during manufacturing.

    • Tick icon

      Helps protect the efficacy of antibiotics in fighting diseases.

    • Icon description

      Aligned with the AMR Industry Alliance’s Antibiotic Manufacturing Standard (May 2025).

    • Icon description

      BSI Kitemark certification further assures healthcare procurers, investors, and customers.

    Commitment to tackling AMR

    GSK is playing a leading role in the fight against AMR. Key figures include:

    • 12

      R&D projects targeting pathogens deemed ‘critical’ or ‘urgent’ by WHO and US CDC.

    • All

      antibiotic sites certified worldwide.

    • 100%

      reported compliance with antibiotic discharge limits (2026 AMR Benchmark).

    • £45 million

      Pledged to the Fleming Initiative, to develop new AMR interventions.

    • 22

      Years of running the Survey of Antibiotic Resistance, a multinational surveillance programme.

    • 70

      Years of expertise in infectious disease R&D.

    “This milestone reflects our dedication to responsible manufacturing and reducing our environmental impact.” 

    Regis Simard President, Global Supply Chain, GSK
    Young smiling female employee in a pharmaceutical laboratory completely dressed in a protective workwear seen holding a big plastic box
    Why BSI

    Working in partnership for a healthier world

    This Kitemark was developed by BSI with the AMR Industry Alliance (AMRIA) to bring trust, evidence and visibility to antibiotic supply chains.

    By certifying every antibiotic manufacturing site, GSK has shown real leadership for the pharmaceutical sector. Independent assessment gives patients and healthcare systems confidence in how vital medicines are made.

    Contact Us

    Addressing antimicrobial resistance together

    Build trust and confidence with the BSI Kitemark™ for minimized risk of antimicrobial resistance.

    Get in touch